These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
83 related articles for article (PubMed ID: 1425958)
1. JMV 449: a pseudopeptide analogue of neurotensin-(8-13) with highly potent and long-lasting hypothermic and analgesic effects in the mouse. Dubuc I; Costentin J; Doulut S; Rodriguez M; Martinez J; Kitabgi P Eur J Pharmacol; 1992 Aug; 219(2):327-9. PubMed ID: 1425958 [TBL] [Abstract][Full Text] [Related]
2. Synthesis and biological effects of c(Lys-Lys-Pro-Tyr-Ile-Leu-Lys-Lys-Pro-Tyr-Ile-Leu) (JMV2012), a new analogue of neurotensin that crosses the blood-brain barrier. Bredeloux P; Cavelier F; Dubuc I; Vivet B; Costentin J; Martinez J J Med Chem; 2008 Mar; 51(6):1610-6. PubMed ID: 18321036 [TBL] [Abstract][Full Text] [Related]
4. In vivo and in vitro structure-activity studies with peptide and pseudopeptide neurotensin analogs suggest the existence of distinct central neurotensin receptor subtypes. Labbé-Jullié C; Dubuc I; Brouard A; Doulut S; Bourdel E; Pelaprat D; Mazella J; Martinez J; Rostène W; Costentin J J Pharmacol Exp Ther; 1994 Jan; 268(1):328-36. PubMed ID: 8301574 [TBL] [Abstract][Full Text] [Related]
5. Reduced peptide bond pseudopeptide analogues of neurotensin: binding and biological activities, and in vitro metabolic stability. Lugrin D; Vecchini F; Doulut S; Rodriguez M; Martinez J; Kitabgi P Eur J Pharmacol; 1991 Nov; 205(2):191-8. PubMed ID: 1812009 [TBL] [Abstract][Full Text] [Related]
6. Neuroprotective effect of the neurotensin analogue JMV-449 in a mouse model of permanent middle cerebral ischaemia. Torup L; Borsdal J; Sager T Neurosci Lett; 2003 Nov; 351(3):173-6. PubMed ID: 14623134 [TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological activities of psi (CH2NH) pseudopeptide analogues of the C-terminal hexapeptide of neurotensin. Couder J; Tourwé D; Van Binst G; Schuurkens J; Leysen JE Int J Pept Protein Res; 1993 Feb; 41(2):181-4. PubMed ID: 8458692 [TBL] [Abstract][Full Text] [Related]
8. Highly potent neurotensin analog that causes hypothermia and antinociception. Tyler-McMahon BM; Stewart JA; Farinas F; McCormick DJ; Richelson E Eur J Pharmacol; 2000 Feb; 390(1-2):107-11. PubMed ID: 10708713 [TBL] [Abstract][Full Text] [Related]
9. Ketomethylene and (cyanomethylene)amino pseudopeptide analogues of the C-terminal hexapeptide of neurotensin. González-Muñiz R; García-López MT; Gómez-Monterrey I; Herranz R; Jimeno ML; Suárez-Gea ML; Johansen NL; Madsen K; Thøgersen H; Suzdak P J Med Chem; 1995 Mar; 38(6):1015-21. PubMed ID: 7699693 [TBL] [Abstract][Full Text] [Related]
10. Endomorphin 1[psi] and endomorphin 2[psi], endomorphins analogues containing a reduced (CH2NH) amide bond between Tyr1 and Pro2, display partial agonist potency but significant antinociception. Zhao QY; Chen Q; Yang DJ; Feng Y; Long Y; Wang P; Wang R Life Sci; 2005 Jul; 77(10):1155-65. PubMed ID: 15878600 [TBL] [Abstract][Full Text] [Related]
12. Tolerance to the hypothermic but not to the analgesic effect of [D-Trp11]neurotensin during the semichronic intracerebroventricular infusion of the peptide in rats. Dubuc I; Pain C; Suaudeau C; Costentin J Peptides; 1994; 15(2):303-7. PubMed ID: 8008636 [TBL] [Abstract][Full Text] [Related]
13. Comparative antipsychotic profiles of neurotensin and a related systemically active peptide agonist. Sarhan S; Hitchcock JM; Grauffel CA; Wettstein JG Peptides; 1997; 18(8):1223-7. PubMed ID: 9396065 [TBL] [Abstract][Full Text] [Related]
14. The stimulatory effects of neurotensin and related peptides in rat stomach strips and guinea-pig atria. Quirion R; Regoli D; Rioux F; St-Pierre S Br J Pharmacol; 1980 Jan; 68(1):83-91. PubMed ID: 7357202 [TBL] [Abstract][Full Text] [Related]
15. Metabolically stable neurotensin analogs exert potent and long-acting analgesia without hypothermia. Vivancos M; Fanelli R; Besserer-Offroy É; Beaulieu S; Chartier M; Resua-Rojas M; Mona CE; Previti S; Rémond E; Longpré JM; Cavelier F; Sarret P Behav Brain Res; 2021 May; 405():113189. PubMed ID: 33607165 [TBL] [Abstract][Full Text] [Related]
16. Synthesis and analgesic effects of N-[3-[(hydroxyamino) carbonyl]-1-oxo-2(R)-benzylpropyl]-L-isoleucyl-L-leucine, a new potent inhibitor of multiple neurotensin/neuromedin N degrading enzymes. Doulut S; Dubuc I; Rodriguez M; Vecchini F; Fulcrand H; Barelli H; Checler F; Bourdel E; Aumelas A; Lallement JC J Med Chem; 1993 May; 36(10):1369-79. PubMed ID: 8496905 [TBL] [Abstract][Full Text] [Related]
18. Effect of a novel selective and potent phosphinic peptide inhibitor of endopeptidase 3.4.24.16 on neurotensin-induced analgesia and neuronal inactivation. Vincent B; Jiracek J; Noble F; Loog M; Roques B; Dive V; Vincent JP; Checler F Br J Pharmacol; 1997 Jun; 121(4):705-10. PubMed ID: 9208137 [TBL] [Abstract][Full Text] [Related]
19. In vivo behavioral effects of stable, receptor-selective neurotensin[8-13] analogues that cross the blood-brain barrier. Kokko KP; Hadden MK; Price KL; Orwig KS; See RE; Dix TA Neuropharmacology; 2005 Mar; 48(3):417-25. PubMed ID: 15721174 [TBL] [Abstract][Full Text] [Related]
20. Agonist properties of a stable hexapeptide analog of neurotensin, N alpha MeArg-Lys-Pro-Trp-tLeu-Leu (NT1). Akunne HC; Demattos SB; Whetzel SZ; Wustrow DJ; Davis DM; Wise LD; Cody WL; Pugsley TA; Heffner TG Biochem Pharmacol; 1995 Apr; 49(8):1147-54. PubMed ID: 7748196 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]